क्यूआर कोड

Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

Abstract Mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%–4%) driver mutation in non‐small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping‐mutated NSCLC. However, its feasibility for perioperative...

पूर्ण विवरण

में बचाया:
मुख्य लेखकों: Rongzhen Li, Xiaoyan Liu, Yan Xu, Jing Zhao, Wei Zhong, Xiaoxing Gao, Minjiang Chen, Mengzhao Wang
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Wiley 2024-11-01
श्रृंखला:Thoracic Cancer
विषय:
MET exon 14 skipping mutation
neoadjuvant
non‐small cell lung cancer
tepotinib
ऑनलाइन पहुंच:https://doi.org/10.1111/1759-7714.15459
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन